ArticleBMC nephrology2021
Gut microbiota in Immunoglobulin A Nephropathy: a Malaysian Perspective.
Article in BMC nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Gut Microbiome Characteristics in IgA Nephropathy: Qualitative and Quantitative Analysis from Observational Studies.Frontiers in cellular and infection microbiology · 2022Pooled it
- Targeted release of budesonide modulates key gut microbial abnormalities in immunoglobulin A nephropathy.Frontiers in immunology · 2026Article
- Exploring the mediating role of immune cells in the pathogenesis of IgA nephropathy through the inflammatory axis of gut microbiota from a genomic perspective.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Article
- Characteristics, pathogenic and therapeutic role of gut microbiota in immunoglobulin A nephropathy.Frontiers in immunology · 2025Review
- The evolving understanding of systemic mechanisms in organ-specific IgA nephropathy: a focus on gut-kidney crosstalk.Theranostics · 2025Review
- Healthy human gut microbiome: Towards standardized research.AIMS microbiology · 2025Review
- Humoral immune responses primed by the alteration of gut microbiota were associated with galactose-deficient IgA1 production in IgA nephropathy.Frontiers in immunology · 2024Article
- Chronic kidney disease and gut microbiota.Heliyon · 2023Review
- The Effects of Specific Gut Microbiota and Metabolites on IgA Nephropathy-Based on Mendelian Randomization and Clinical Validation.Nutrients · 2023Article
- Gut Microbiota in Chronic Kidney Disease: From Composition to Modulation towards Better Outcomes-A Systematic Review.Journal of clinical medicine · 2023Review
- Association between salivary microbiota and renal function in renal transplant patients during the perioperative period.Frontiers in microbiology · 2023Article
- Probiotics ameliorate IgA nephropathy by improving gut dysbiosis and blunting NLRP3 signaling.Journal of translational medicine · 2022Article
- Findings on the Relationship Between Intestinal Microbiome and Vasculitis.Frontiers in cellular and infection microbiology · 2022Review
- Development and validation of diagnostic models for immunoglobulin A nephropathy based on gut microbes.Frontiers in cellular and infection microbiology · 2022Article
- Gut Microbes in Immunoglobulin A Nephropathy and Their Potential Therapeutic Applications.Frontiers in medicine · 2022Review
- A Link between Chronic Kidney Disease and Gut Microbiota in Immunological and Nutritional Aspects.Nutrients · 2021Review
- IgA Nephropathy: Emerging Mechanisms of Disease.Indian journal of nephrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe alteration of the gut microbiome in the gut-kidney axis has been associated with a pro-inflammatory state and chronic kidney disease (CKD). A small-scaled Italian study has shown an association between the gut microbiome and Immunoglobulin A Nephropathy (IgAN). However, there is no data on gut microbiota in IgAN in the Asian population. This study compares the gut microbial abundance and diversity between healthy volunteers and Malaysian IgAN cohort.
methodsA comparative cross-sectional study was conducted involving biopsy-proven IgAN patients in clinical remission with matched controls in a Malaysian tertiary centre. Demographic data, routine blood and urine results were recorded. Stool samples were collected and their DNA was extracted by 16S rRNA gene sequencing to profile their gut microbiota.
resultsThirty-six IgAN patients (13 male; 23 female) with the mean age of 45.5 ± 13.4 years and median estimated glomerular filtration rate (eGFR) of 79.0 (62.1-92.2) mls/min/1.73m
conclusionAlthough we found no differences in OTU and alpha diversity between IgAN in remission and control cohort, there were some differences between the two groups at phylum level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.